Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acadia Pharmaceuticals has reported positive top-line results from a proof-of-concept clinical study assessing its experimental drug ACP-103 on deep, or slow wave, sleep in healthy older volunteers.
Subscribe to our email newsletter
Results of the study demonstrated that ACP-103 induced a robust and statistically significant increase in slow wave sleep that was dose-related. ACP-103 treatment also had a positive impact on measures for sleep maintenance, including decreases in the number of awakenings after sleep onset and in the time awake after sleep onset.
ACP-103 is a serotonin 5-HT2A inverse agonist that works by blocking the activity of this key receptor.
“These data provide a proof-of-concept of the ability of ACP-103 to improve the quality of sleep by increasing slow wave sleep,” said Dr Uli Hacksell, CEO of Acadia. “This suggests that ACP-103 has potential as a novel treatment for sleep maintenance insomnia.”
“Acadia is currently in phase II clinical development with ACP-103 for use in schizophrenia and treatment-induced dysfunctions in Parkinson’s disease, two indications with patients who frequently suffer from sleep disturbances,” continued Dr Hacksell.